Zinc transporter 8

Fractyl Announces Closing of $100 Million Series F Financing to Expand Clinical Development Programs in Type 2 Diabetes

Retrieved on: 
Wednesday, June 16, 2021
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical trials, Clinical medicine, Organ systems, Branches of biology, Diabetes, Insulin, Type 2 diabetes, T2D, Zinc transporter 8, Diabetes management

Fractyl Health , a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced the closing of a $100 million Series F financing.

Key Points: 
  • Fractyl Health , a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced the closing of a $100 million Series F financing.
  • This financing will enable the expansion and acceleration of our clinical development efforts with the goal of reducing insulin dependence for patients with type 2 diabetes on a global scale.
  • Fractyl recently obtained FDA Breakthrough Device Designation for Revita DMR in patients with type 2 diabetes (T2D) who are currently treated with insulin.
  • We are enthusiastically committed to supporting Fractyl as it drives forward its development and commercial programs to realize the full range of Revitas potential in type 2 diabetes.

Medality Medical Commences Clinical Trial for Type 2 Diabetes

Retrieved on: 
Monday, September 16, 2019
Clinical trials, Teens, Biotechnology, Parenting, Children, Women, Seniors, Health, Other Science, Research, MEN, Family, Consumer, Other Technology, Science, Diabetes, General Health, Technology, Organ systems, Medicine, Endocrine system, Diabetes, Type 2 diabetes, Obesity, T2D, Zinc transporter 8, Samuel Dagogo-Jack, Clinical trials, Teens, Biotechnology, Parenting, Children, Women, Seniors, Health, Other Science, Research, MEN, Family, Consumer, Other Technology, Science, Diabetes, General Health, Technology, Organ systems, Medicine, Endocrine system, Diabetes, Type 2 diabetes, Obesity, T2D, Zinc transporter 8, Samuel Dagogo-Jack

Patient recruitment is currently underway for the first in-human clinical trial for Medality Medicals proprietary medical device, HydraSolve T2D Visceral Fat Extraction System (HydraSolve T2D System) and the associated surgical procedure designed to reverse type 2 diabetes and associated obesity.

Key Points: 
  • Patient recruitment is currently underway for the first in-human clinical trial for Medality Medicals proprietary medical device, HydraSolve T2D Visceral Fat Extraction System (HydraSolve T2D System) and the associated surgical procedure designed to reverse type 2 diabetes and associated obesity.
  • The target group consists of overweight/obese individuals with type 2 diabetes who have not achieved targeted levels of blood glucose control using oral diabetes medications.
  • Medality Medical LLC , a privately funded (including an NIH grant) medical technology company, is focused on reversing type 2 diabetes and associated obesity.
  • Medality Medical is currently raising additional capital to fund the clinical trial and expand its IP portfolio.